| |
Article Title |
Author(s) |
Pages |
|
|
|
Contributors
|
|
iii-v
|
|
|
|
Contents
|
|
vii-ix
|
|
|
|
Forthcoming Issues
|
|
x
|
|
|
|
Clinical Drug Development in 2012
Hosting as editor this 2012 issue of Hematology Oncology Clinics of North America is an opportunity to reflect on trends in clinical drug development. In particular, awareness of the incredible possib...
|
Franco Muggia
|
xi-xii
|
|
|
|
Therapeutic Antibodies Against Cancer
Antibody-based therapeutics against cancer are highly successful and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use i...
|
Mark J. Adler,
Dimiter S. Dimitrov
|
447-481
|
|
|
|
mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
05 April 2012
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase. It is ubiquitously expressed in cells and is a therapeutic target for the cancer treatment arsenal. Despite the great respons...
|
Alejandro Gomez-Pinillos,
Anna C. Ferrari
|
483-505
|
|
|
|
Topoisomerase 1 Inhibitors and Cancer Therapy
Topoisomerase 1 inhibitors cure human cancer xenografts in animal models, more so than most other chemotherapy agents. However, their activity in patients with cancer is modest. Ongoing research is st...
|
Julia Moukharskaya,
Claire Verschraegen
|
507-525
|
|
|
|
Targeting the Insulin Growth Factor Receptor 1
29 February 2012
The IGF axis is a tightly controlled endocrine system that regulates cell growth and development, known to have an important function in cancer biology. IGF1 and IGF2 can promote cancer growth in a GH...
|
Fernanda I. Arnaldez,
Lee J. Helman
|
527-542
|
|
|
|
Targeting Angiogenesis in Gynecologic Cancers
Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to i...
|
Behrouz Zand,
Robert L. Coleman,
Anil K. Sood
|
543-563
|
|
|
|
Targeting the Hedgehog Pathway: Role in Cancer and Clinical Implications of Its Inhibition
The Hedgehog (Hh) pathway is a signaling cascade that is evolutionally highly conserved and plays an important role in embryonic pattern formation and stem cell response to tissue damage. Given the pi...
|
Deirdre J. Cohen
|
565-588
|
|
|
|
Tyrosine Kinase Inhibitors in Lung Cancer
05 March 2012
Identification of driver mutations in growth related protein kinases, especially tyrosine kinases, has led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, in...
|
Anish Thomas,
Arun Rajan,
Giuseppe Giaccone
|
589-605
|
|
|
|
Antimitotic Inhibitors
26 March 2012
Of the agents available in the treatment of both solid and hematologic cancers, microtubule-targeted agents are among the most widely used and exploiting other mechanisms involving the microtubule and...
|
Susana M. Campos,
Don S. Dizon
|
607-628
|
|
|
|
The Antifolates
This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mecha...
|
Michele Visentin,
Rongbao Zhao,
I. David Goldman
|
629-648
|
|
|
|
Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment
Recently, the development of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer suscep...
|
Sook Ryun Park,
Alice Chen
|
649-670
|
|
|
|
Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma
29 March 2012
Histone deacetylase inhibitors (HDACI) have allowed pharmacologic manipulation of deregulated genes in cancer cells and have shown single-agent activity against T cell lymphomas, cutaneous T cell lymp...
|
Jasmine Zain
|
671-704
|
|
|
|
Index
|
|
705-714
|
|
